Certified by Founder Lodge
OrsoBio
United States - Palo Alto, CA
START UP
1 Disclosed Funding Rounds $60,000,000
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidem
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| November, 08 ,2023 | Series A | $60,000,000 | |
| September, 10 ,2024 | Series B | $67,000,000.00 |
Eli Lilly and Company
Enavate Sciences
Longitude Capital
Samsara BioCapital
NuevaBio
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
